Concepts (91)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ribose | 2 | 2020 | 63 | 1.170 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 5 | 2024 | 936 | 1.070 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2024 | 1094 | 0.880 |
Why?
|
| Cysteine | 2 | 2020 | 895 | 0.820 |
Why?
|
| Antioxidants | 2 | 2020 | 1673 | 0.660 |
Why?
|
| Protective Agents | 1 | 2020 | 150 | 0.630 |
Why?
|
| Stromal Cells | 1 | 2024 | 1337 | 0.620 |
Why?
|
| Lymphocytes | 1 | 2024 | 2611 | 0.530 |
Why?
|
| Hyperplasia | 1 | 2019 | 1153 | 0.510 |
Why?
|
| Formaldehyde | 1 | 2016 | 361 | 0.490 |
Why?
|
| Precancerous Conditions | 2 | 2019 | 984 | 0.470 |
Why?
|
| Gene Dosage | 3 | 2021 | 1221 | 0.460 |
Why?
|
| Apolipoproteins E | 1 | 2020 | 1459 | 0.450 |
Why?
|
| Breast Neoplasms | 7 | 2024 | 21162 | 0.410 |
Why?
|
| Glutathione | 1 | 2014 | 585 | 0.390 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 3939 | 0.380 |
Why?
|
| Lipoproteins, LDL | 1 | 2014 | 643 | 0.380 |
Why?
|
| Lipoprotein(a) | 1 | 2014 | 490 | 0.340 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2024 | 1105 | 0.260 |
Why?
|
| DNA Copy Number Variations | 5 | 2022 | 2046 | 0.240 |
Why?
|
| Atherosclerosis | 1 | 2020 | 3431 | 0.220 |
Why?
|
| DNA | 1 | 2016 | 7211 | 0.210 |
Why?
|
| Smad4 Protein | 1 | 2021 | 193 | 0.170 |
Why?
|
| Breast | 2 | 2019 | 1975 | 0.170 |
Why?
|
| Sequence Analysis, DNA | 2 | 2022 | 4775 | 0.150 |
Why?
|
| Mammography | 2 | 2019 | 2434 | 0.140 |
Why?
|
| Paraffin | 1 | 2016 | 36 | 0.140 |
Why?
|
| Barrett Esophagus | 1 | 2021 | 494 | 0.140 |
Why?
|
| Lipids | 2 | 2020 | 3344 | 0.130 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 2014 | 45 | 0.120 |
Why?
|
| Dinoprost | 1 | 2014 | 139 | 0.120 |
Why?
|
| Gene Library | 1 | 2016 | 1061 | 0.110 |
Why?
|
| Oxidation-Reduction | 1 | 2020 | 2225 | 0.110 |
Why?
|
| Genomics | 2 | 2022 | 5916 | 0.110 |
Why?
|
| Carcinoma in Situ | 1 | 2019 | 789 | 0.110 |
Why?
|
| Apolipoproteins B | 1 | 2014 | 386 | 0.100 |
Why?
|
| Neoplasms | 1 | 2022 | 22385 | 0.100 |
Why?
|
| Forkhead Transcription Factors | 1 | 2020 | 1623 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 3617 | 0.100 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2016 | 330 | 0.100 |
Why?
|
| Alleles | 1 | 2022 | 6892 | 0.090 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 1885 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 3794 | 0.080 |
Why?
|
| Female | 9 | 2024 | 397089 | 0.070 |
Why?
|
| DNA Repair | 1 | 2016 | 2048 | 0.070 |
Why?
|
| Mutation | 2 | 2022 | 30228 | 0.060 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 3236 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 3666 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 5538 | 0.050 |
Why?
|
| Genome, Human | 1 | 2016 | 4450 | 0.050 |
Why?
|
| Humans | 10 | 2024 | 768393 | 0.050 |
Why?
|
| Oxygen | 1 | 2014 | 4273 | 0.050 |
Why?
|
| Prognosis | 3 | 2020 | 30022 | 0.050 |
Why?
|
| Mice | 3 | 2021 | 82017 | 0.050 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 9562 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 22355 | 0.050 |
Why?
|
| Disease Progression | 1 | 2018 | 13646 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 17135 | 0.040 |
Why?
|
| Victoria | 1 | 2019 | 64 | 0.040 |
Why?
|
| Liver | 1 | 2014 | 7574 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2020 | 2952 | 0.040 |
Why?
|
| Receptor, erbB-2 | 2 | 2020 | 2588 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2021 | 948 | 0.040 |
Why?
|
| Animals | 3 | 2021 | 169337 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 16028 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2021 | 1064 | 0.030 |
Why?
|
| GATA3 Transcription Factor | 1 | 2017 | 163 | 0.030 |
Why?
|
| Aged | 3 | 2024 | 171562 | 0.030 |
Why?
|
| Oncogenes | 1 | 2021 | 1235 | 0.030 |
Why?
|
| Middle Aged | 3 | 2024 | 223491 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2016 | 41795 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2021 | 2940 | 0.030 |
Why?
|
| Adult | 3 | 2024 | 223640 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2021 | 2003 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 906 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2020 | 2574 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 4921 | 0.020 |
Why?
|
| Base Sequence | 1 | 2021 | 12422 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 15649 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4411 | 0.020 |
Why?
|
| Cell Line | 1 | 2021 | 15597 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 4785 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 59686 | 0.010 |
Why?
|
| Registries | 1 | 2019 | 8379 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 15455 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 10267 | 0.010 |
Why?
|
| Phenotype | 1 | 2019 | 16721 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2021 | 23631 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 18048 | 0.010 |
Why?
|
| Male | 1 | 2014 | 364902 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2019 | 54920 | 0.010 |
Why?
|
Concepts
(91)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(7)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_